Navigation Links
Biocept CEO Michael W. Nall to Present at the Personalized Medicine World Conference

SAN DIEGO, Jan. 25, 2016 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing blood-based biomarkers to improve the detection and treatment of cancer, announces that President and CEO Michael W. Nall will speak at today's "Clinical Testing Applications of Liquid Biopsy" session at the Personalized Medicine World Conference (PMWC) 2016.  The conference is being held in Mountain View, Calif.

"We are happy to participate in this important conference that brings together experts from diverse fields to discuss innovations aimed at advancing personalized medicine," said Mr. Nall.  "I am proud of Biocept's role in providing assays that use a simple blood draw to profile and monitor multiple types of cancers.  Our tests provide actionable information that can assist physicians with personalizing treatments for their patients with cancer in order to improve outcomes."  

About the Personalized Medicine World Conference

Personalized Medicine World Conference (PMWC), in its 10th year, is an independent conference that attracts recognized authorities and experts across healthcare and biotechnology sectors. The conference showcases practical content that helps close the knowledge gap between different sectors, thereby catalyzing cross-functional collaboration to further adoption of personalized medicine in the clinic.  PMWC 2016 is expected to bring together nearly 1,100 key opinion leaders and stakeholders in the personalized medicine field.

About Biocept

Biocept, Inc. is a commercial-stage molecular diagnostics company that utilizes a proprietary technology platform and a standard blood sample to provide physicians with important prognostic and predictive information to enhance individual treatment of patients with cancer. Biocept's patented technology platform captures and analyzes circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in plasma. Biocept currently offers assays for gastric cancer, breast cancer, lung cancer, colorectal cancer, prostate cancer and melanoma, and plans to introduce additional CLIA-validated assays in the near term. For additional information, please visit

Logo -


SOURCE Biocept, Inc.
Copyright©2016 PR Newswire.
All rights reserved

Related biology technology :

1. Biocept to Hold 2015 Third Quarter Conference Call on November 5
2. Biocept Reports Third Quarter 2015 Financial Results
3. Biocept Expands Patent Protection in Europe
4. Biocept Announces Collaboration with Baylor College of Medicine to Develop Liquid Biopsy Tests for Estrogen Receptor Gene
5. Biocept Launches Blood-based Test for Prostate Cancer and Expands Offering in Breast Cancer
6. Orexigen CEO Michael Narachi Elected to PhRMA Board of Directors
7. 2012-2013 Michael E. DeBakey Journalism Award Winners Announced
8. Validant Names Michael Beatrice as New Company President
9. Health Decisions CEO Michael Rosenberg Named a Business Leader Top Entrepreneur for 2013
10. Intra-Cellular Therapies Appoints Professor Sir Michael Rawlins to its Board of Directors
11. Envera Appoints Michael McErlean Fermentation Manager
Post Your Comments:
(Date:1/23/2020)... ... January 22, 2020 , ... Ideal ... cosmetic surgery industry at two recent North American investor forums specializing in medical ... Genuity Medical Technologies & Diagnostics Forum on November 21, 2019 in New York ...
(Date:1/10/2020)... ... 09, 2020 , ... A new report from Tufts ... qualification process, a critical element of clinical trial set up and execution. According ... qualification process creates delays in initiation in 7% of clinical trials for biopharma ...
(Date:1/7/2020)... ... 07, 2020 , ... Absolute Antibody Ltd. , an ... its VivopureX™ recombinant mouse antibodies for in vivo research in mouse models. The ... which Absolute Antibody has engineered into mouse-anti-mouse recombinant versions to improve research results. ...
(Date:12/31/2019)... ... 2019 , ... Vici Health Sciences announces it ... Maryland. Emphasis will be in expanding capabilities in both oral and parenteral dosage ... well positioned to meet the growing demand for its pharmaceutical formulation and analytical ...
Breaking Biology Technology:
(Date:2/6/2020)... ... February 06, 2020 , ... ... unique lab-made bioresearch materials, today announced an agreement with The Good Food ... seafood a reality. Under the partnership, terrestrial meat and aquatic cell lines will ...
(Date:2/5/2020)... ... 05, 2020 , ... LabKey has released Sample Manager, ... sample processing within laboratories. , Built with input from a Product Advisory ... LabKey Sample Manager has been designed with an intuitive user interface providing a ...
(Date:1/30/2020)... ... 30, 2020 , ... Accelera Canada , a full-service firm delivering end-to-end ... pleased to announce that the company has opened the doors of its first office ... , “We are so thrilled to now have all our partners and their ...
Breaking Biology News(10 mins):